These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold. Kuduk SD; Chang RK; Di Marco CN; Pitts DR; Greshock TJ; Ma L; Wittmann M; Seager MA; Koeplinger KA; Thompson CD; Hartman GD; Bilodeau MT; Ray WJ J Med Chem; 2011 Jul; 54(13):4773-80. PubMed ID: 21682298 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist. Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436 [TBL] [Abstract][Full Text] [Related]
4. SAR studies on carboxylic acid series M(1) selective positive allosteric modulators (PAMs). Kuduk SD; Beshore DC Curr Top Med Chem; 2014; 14(15):1738-54. PubMed ID: 25176125 [TBL] [Abstract][Full Text] [Related]
5. Using cholinergic M1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communication. Chambon C; Jatzke C; Wegener N; Gravius A; Danysz W Eur J Pharmacol; 2012 Dec; 697(1-3):73-80. PubMed ID: 23085025 [TBL] [Abstract][Full Text] [Related]
13. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions. Bolbecker AR; Shekhar A Handb Exp Pharmacol; 2012; (208):167-90. PubMed ID: 22222699 [TBL] [Abstract][Full Text] [Related]
14. Diverse Effects on M Rook JM; Abe M; Cho HP; Nance KD; Luscombe VB; Adams JJ; Dickerson JW; Remke DH; Garcia-Barrantes PM; Engers DW; Engers JL; Chang S; Foster JJ; Blobaum AL; Niswender CM; Jones CK; Conn PJ; Lindsley CW ACS Chem Neurosci; 2017 Apr; 8(4):866-883. PubMed ID: 28001356 [TBL] [Abstract][Full Text] [Related]
15. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease. Melancon BJ; Tarr JC; Panarese JD; Wood MR; Lindsley CW Drug Discov Today; 2013 Dec; 18(23-24):1185-99. PubMed ID: 24051397 [TBL] [Abstract][Full Text] [Related]
16. Muscarinic acetylcholine receptors as CNS drug targets. Langmead CJ; Watson J; Reavill C Pharmacol Ther; 2008 Feb; 117(2):232-43. PubMed ID: 18082893 [TBL] [Abstract][Full Text] [Related]
17. Muscarinic receptor pharmacology and circuitry for the modulation of cognition. Bubser M; Byun N; Wood MR; Jones CK Handb Exp Pharmacol; 2012; (208):121-66. PubMed ID: 22222698 [TBL] [Abstract][Full Text] [Related]
18. AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Bradley SR; Lameh J; Ohrmund L; Son T; Bajpai A; Nguyen D; Friberg M; Burstein ES; Spalding TA; Ott TR; Schiffer HH; Tabatabaei A; McFarland K; Davis RE; Bonhaus DW Neuropharmacology; 2010 Feb; 58(2):365-73. PubMed ID: 19835892 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor. Mistry SN; Valant C; Sexton PM; Capuano B; Christopoulos A; Scammells PJ J Med Chem; 2013 Jun; 56(12):5151-72. PubMed ID: 23718562 [TBL] [Abstract][Full Text] [Related]
20. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. Jones CK; Brady AE; Davis AA; Xiang Z; Bubser M; Tantawy MN; Kane AS; Bridges TM; Kennedy JP; Bradley SR; Peterson TE; Ansari MS; Baldwin RM; Kessler RM; Deutch AY; Lah JJ; Levey AI; Lindsley CW; Conn PJ J Neurosci; 2008 Oct; 28(41):10422-33. PubMed ID: 18842902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]